Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) Director Mark Steven Davis sold 6,100 shares of the stock in a transaction that occurred on Wednesday, November 18th. The stock was sold at an average price of $5.62, for a total value of $34,282.00. Following the completion of the transaction, the director directly owned 100,565 shares of the company’s stock, valued at $565,175.30. This trade represents a 5.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Myriad Genetics Stock Up 0.2%
MYGN opened at $5.54 on Friday. The stock’s 50 day moving average price is $4.93 and its 200 day moving average price is $4.62. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.98 and a quick ratio of 1.77. The stock has a market cap of $531.40 million, a P/E ratio of -4.07 and a beta of 1.62. Myriad Genetics, Inc. has a 12 month low of $2.74 and a 12 month high of $8.09.
Myriad Genetics (NASDAQ:MYGN – Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.09. Myriad Genetics had a negative return on equity of 19.87% and a negative net margin of 16.07%. The company had revenue of $202.70 million during the quarter, compared to analyst estimates of $191.33 million. As a group, research analysts predict that Myriad Genetics, Inc. will post -1.02 earnings per share for the current year.
Institutional Trading of Myriad Genetics
Hedge funds and other institutional investors have recently made changes to their positions in the business. Orbimed Advisors LLC bought a new stake in Myriad Genetics during the first quarter worth approximately $562,500,000. BlackRock Inc. acquired a new position in Myriad Genetics in the second quarter worth approximately $62,184,000. Marshall Wace LLP increased its holdings in shares of Myriad Genetics by 69.5% in the third quarter. Marshall Wace LLP now owns 2,072,548 shares of the company’s stock valued at $8,933,000 after buying an additional 849,744 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Myriad Genetics in the second quarter valued at $8,039,000. Finally, Man Group plc bought a new position in shares of Myriad Genetics in the second quarter valued at $5,189,000. 99.02% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
A number of equities analysts recently issued reports on MYGN shares. Wells Fargo & Company set a $4.50 target price on shares of Myriad Genetics in a research report on Tuesday, October 20th. Wall Street Zen raised shares of Myriad Genetics from a “sell” rating to a “hold” rating in a research note on Saturday, November 7th. Weiss Ratings cut Myriad Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, October 27th. Stephens upped their target price on Myriad Genetics from $3.00 to $6.00 and gave the stock an “equal weight” rating in a research report on Thursday, November 12th. Finally, TD Cowen increased their price target on Myriad Genetics from $4.50 to $6.75 and gave the company a “hold” rating in a research note on Thursday, November 5th. One investment analyst has rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $5.98.
Read Our Latest Research Report on MYGN
Myriad Genetics Company Profile
Myriad Genetics, Inc. is a molecular diagnostics company that develops and provides genetic tests to help inform healthcare decisions. Its offerings include tests for hereditary cancer risk, tumor biology and prognosis, reproductive health, and how patients may respond to certain medications. Its products include MyRisk, which assesses inherited cancer risk; GeneSight, a pharmacogenomic test intended to help guide psychiatric medication decisions; and Prolaris, which helps assess the aggressiveness of prostate cancer.
Recommended Stories
- Five stocks we like better than Myriad Genetics
- Home Depot Posts a Q3 Double Beat, But Is Its Rebound Built to Last?
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
